SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celgene Corporation Release: At American Society of Clinical Oncology, Oral Presentation from Intergroupe Francophone Du Myelome (IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMID® in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant